Stock Evaluator: Boston Scientific Corporation (BSX)

Boston Scientific Corporation BSX

$46.73 0.73 1.59%
July 31, 2026 4:00:02 PM EST November 10, 2021 Volume: 18,685,783
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NYSE | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics BSX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $69,457.4 $337.2 95%
Shares Out (Mil) 1,495.0 41.9 96%
Institutional Ownership 99.8% 77.8% 94%
Float (Mil) 1,482.4 34.7 94%
Beta 0.58 0.85 33%
Avg Daily Volume (000s) 22,937 278 99%
Price Change
(52-week)
(56.2%) 58.7% 13%
Growth BSX Industry
Median
Percentile
(All Stocks)
Sales (5yr) 15.2% 11.8% 73%
Net Income (5yr) 106.3% (5.8%) 99%
EPS (5yr) 91.8% 11.4% 99
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 1.2% (16.3%) 66%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 23 26 27
Current EPS $0.805 $3.304 $3.443
Month Ago EPS $0.839 $3.363 $3.721
# Rev Up 0 1 0
# Rev Down 1 0 1
Three Months Ago EPS $0.845 $3.378 $3.764
Year/Year Chg (10.6%) 70.3% 95.8%
Financials BSX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $20,614 $152 91%
Net Income (TTM) (Mil) $3,565 ($10) 95%
EPS (TTM) $2.405 ($0.500) 75%
Operating Cash Flow (TTM) (Mil) $4,341 ($2) 94%
Net Cash Flow (TTM) (Mil) $725 $1 93%
Long-Term Debt (Q1) (Mil) $10,988 $22 92%
Enterprise Value (Q1) (Mil) $103,074 $304 96%
Valuation BSX Industry
Median
Percentile
(All Stocks)
P/B 2.69 2.80 61%
P/E 19.6 31.1 50%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 0.2 1.9 9%
Ratios BSX Industry
Median
Percentile
(All Stocks)
Gross Margin 69.3% 59.1% 81%
Net Margin 17.5% (7.3%) 76%
ROA 8.4% (13.7%) 84%
ROE 14.8% (15.8%) 71%
Liabilities to Assets 41.1% 44.7% 32%
F-Score 7 4 84%

Boston Scientific Corporation did not pass any screens on 7/31/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors